Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP) (PRESAP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00141193
Recruitment Status : Completed
First Posted : September 1, 2005
Last Update Posted : August 6, 2008
Sponsor:
Information provided by:
Pfizer

Brief Summary:
This study is a prospective, randomized, double-blind, placebo-controlled, multi-center trial to compare the efficacy and safety of celecoxib 400mg QD versus placebo in reducing the occurrence of new colorectal adenomas post-polypectomy at Month 13 (Year 1) and Month 37 (Year 3) of study drug administration.

Condition or disease Intervention/treatment Phase
Colorectal Adenoma Drug: Celecoxib Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1561 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Clinical Protocol For a Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Celecoxib (SC-58635) In The Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)
Study Start Date : February 2001
Actual Primary Completion Date : May 2007
Actual Study Completion Date : May 2007

Resource links provided by the National Library of Medicine

Drug Information available for: Celecoxib

Arm Intervention/treatment
Placebo Comparator: A Drug: Celecoxib



Primary Outcome Measures :
  1. To evaluate the effects of celecoxib in reducing the proportion of subjects with new colorectal adenomas post baseline polypectomy after Month 13 (Year 1) and Month 37 (Year 3) of study drug administration. [ Time Frame: 3 years ]

Secondary Outcome Measures :
  1. The number of colorectal adenomas in study subjects [ Time Frame: 3 years ]
  2. the histopathologic grade of colorectal adenomas [ Time Frame: 3 years ]
  3. the size of colorectal adenomas measured after one year and three years of study drug use. [ Time Frame: 3 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The subject has had a documented colonoscopy to the cecum performed by a study-related physician with adequate preparation resulting in diagnosis and clearance of an adenomatous polyp(s) within 4 months prior to randomization.
  • The subject is willing to abstain from chronic use of all NSAIDs or COX-2 inhibitors excluding aspirin at cardioprotective doses for the duration of the study.

Exclusion Criteria:

  • The subject has a history of Familial Adenomatous Polyposis or Hereditary Non-Polyposis Colorectal Cancer.
  • The subject has a history of inflammatory bowel disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00141193


  Hide Study Locations
Locations
Layout table for location information
United States, California
Pfizer Investigational Site
San Diego, California, United States, 92123
Pfizer Investigational Site
San Kiego, California, United States, 92123
United States, Illinois
Pfizer Investigational Site
North Chicago, Illinois, United States, 60064
Pfizer Investigational Site
Oak Park, Illinois, United States, 60304
United States, Maryland
Pfizer Investigational Site
Baltimore, Maryland, United States, 21229
Pfizer Investigational Site
Baltimore, Maryland, United States
United States, Pennsylvania
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States, 19107-5244
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States, 19107
United States, Texas
Pfizer Investigational Site
Houston, Texas, United States, 77030
United States, Virginia
Pfizer Investigational Site
Richmond, Virginia, United States, 23249
Australia, Queensland
Pfizer Investigational Site
Townsville, Queensland, Australia, 4812
Australia, Victoria
Pfizer Investigational Site
Geelong, Victoria, Australia, 3219
Belgium
Pfizer Investigational Site
Brussels, Belgium, 1090
Pfizer Investigational Site
Bruxelles, Belgium, 1070
Pfizer Investigational Site
Bruxelles, Belgium, 1200
Pfizer Investigational Site
Gent, Belgium, 9000
Brazil
Pfizer Investigational Site
Porto Alegre, RS, Brazil, 90035-003
Pfizer Investigational Site
São Paulo, SP, Brazil, 01509-900
Canada, Alberta
Pfizer Investigational Site
Edmonton, Alberta, Canada, T6G 2B7
Canada, British Columbia
Pfizer Investigational Site
Abbotsford, British Columbia, Canada, V2S 3N5
Pfizer Investigational Site
Vancouver, British Columbia, Canada, V5Z 1J3
Pfizer Investigational Site
Vancouver, British Columbia, Canada, V6Z 1Y6
Canada, Ontario
Pfizer Investigational Site
Kingston, Ontario, Canada, K7L 5G2
Pfizer Investigational Site
London, Ontario, Canada, N6A 4G5
Canada
Pfizer Investigational Site
St. John's, Canada, A1B 3V6
Chile
Pfizer Investigational Site
Santiago, RM, Chile
China
Pfizer Investigational Site
Beijing, China, 10053
Pfizer Investigational Site
Beijing, China, 100730
Czech Republic
Pfizer Investigational Site
Brno, Czech Republic
Pfizer Investigational Site
Hradec Kralove, Czech Republic, 500 12
Pfizer Investigational Site
Liberec, Czech Republic, 460 63
Pfizer Investigational Site
Prague 10, Czech Republic, 10034
Pfizer Investigational Site
Prague 6, Czech Republic, 16 02
Pfizer Investigational Site
Prague, Czech Republic, 11833
Pfizer Investigational Site
Prague, Czech Republic
Denmark
Pfizer Investigational Site
Arhus C, Denmark, 8000
Finland
Pfizer Investigational Site
Oulu, Finland, FIN-90221
France
Pfizer Investigational Site
Bobigny, France, 93009
Pfizer Investigational Site
Lyon, France, 69008
Pfizer Investigational Site
Marseille Cedex 09, France, 13274
Pfizer Investigational Site
Paris Cedex 14, France, 75679
Germany
Pfizer Investigational Site
Berlin, Germany, 13353
Pfizer Investigational Site
Erlangen, Germany, 91052
Pfizer Investigational Site
Freising, Germany, 85356
Pfizer Investigational Site
Hamburg, Germany
Pfizer Investigational Site
Kuenzing, Germany, 94550
Pfizer Investigational Site
Ludwigshafen, Germany, 67063
Pfizer Investigational Site
Marburg, Germany, 35055
Pfizer Investigational Site
Muenchen, Germany, 81669
Pfizer Investigational Site
Munchen, Germany, 81675
Pfizer Investigational Site
Ulm, Germany, 89081
Hong Kong
Pfizer Investigational Site
Hong Kong, Hong Kong
Pfizer Investigational Site
New Territories, Hong Kong
Hungary
Pfizer Investigational Site
Gyor, Hungary, 9023
Pfizer Investigational Site
Szekszárd, Hungary, 7100
Ireland
Pfizer Investigational Site
Wilton, Cork, Ireland
Pfizer Investigational Site
Dublin, Ireland
Israel
Pfizer Investigational Site
Beer-Sheeva, Israel, 84101
Pfizer Investigational Site
Hadera, Israel, 38100
Pfizer Investigational Site
Haifa, Israel
Pfizer Investigational Site
Hashomer, Israel, 52621
Pfizer Investigational Site
Holon, Israel, 58100
Pfizer Investigational Site
Jerusalem, Israel, 91120
Pfizer Investigational Site
Petah-Tikva, Israel
Pfizer Investigational Site
Tel-Aviv, Israel, 64239
Italy
Pfizer Investigational Site
San Giovanni Rotondo, Italy/Foggia/Italy, Italy, 71013
Pfizer Investigational Site
Brescia, Italy, 25123
Pfizer Investigational Site
Milano, Italy, 20141
Pfizer Investigational Site
Roma, Italy, 00144
Pfizer Investigational Site
Roma, Italy, 00153
Pfizer Investigational Site
Siena, Italy, 53100
Netherlands
Pfizer Investigational Site
Maastricht, Netherlands, 6229 HX
Norway
Pfizer Investigational Site
Skien, Norway, 3710
Peru
Pfizer Investigational Site
Lima, Peru, L11
Poland
Pfizer Investigational Site
Warsaw, Poland, 02-781
Portugal
Pfizer Investigational Site
Lisboa, Portugal, 1099-023
Russian Federation
Pfizer Investigational Site
Moscow, Russian Federation, 103006
Pfizer Investigational Site
Moscow, Russian Federation, 113093
Pfizer Investigational Site
Moscow, Russian Federation, 115478
Pfizer Investigational Site
Moscow, Russian Federation, 117415
Pfizer Investigational Site
Moscow, Russian Federation, 123154
Pfizer Investigational Site
Moscow, Russian Federation, 129356
Singapore
Pfizer Investigational Site
Singapore, Singapore, 119074
Pfizer Investigational Site
Singapore, Singapore, 529889
Slovakia
Pfizer Investigational Site
Bratislava, Slovakia, 85107
Pfizer Investigational Site
Bratislava, Slovakia
South Africa
Pfizer Investigational Site
Johannesburg, Gauteng, South Africa, 2157
Pfizer Investigational Site
Johannesburg, Gauteng, South Africa, 2193
Pfizer Investigational Site
Johannesburg, Gauteng, South Africa
Pfizer Investigational Site
Cape Town, Western, South Africa, 7708
Spain
Pfizer Investigational Site
Oviedo, Asturias, Spain, 33006
Pfizer Investigational Site
San Sebastian, Guipuzcoa, Spain, 20014
Pfizer Investigational Site
Palma de Mallorca, Islas Baleares, Spain, 07014
Pfizer Investigational Site
Barcelona, Spain, 08036
Pfizer Investigational Site
Sevilla, Spain, 41071
Sweden
Pfizer Investigational Site
Stockholm, Sweden, 116 91 Stockholm
Pfizer Investigational Site
Uppsala, Sweden, 75185 Uppala
Switzerland
Pfizer Investigational Site
Geneve 14, Switzerland, 1211
Taiwan
Pfizer Investigational Site
Kaohsiung, Taiwan, 813
United Kingdom
Pfizer Investigational Site
Newport, Gwent, United Kingdom, NP9 2UB
Pfizer Investigational Site
Harrow, Middlesex, United Kingdom, HA1 3UJ
Pfizer Investigational Site
Glasgow, United Kingdom, G40SF
Pfizer Investigational Site
Oxford, United Kingdom, OX3 9DU
Uruguay
Pfizer Investigational Site
Montevideo, Uruguay, 11600
Pfizer Investigational Site
Montevideo, Uruguay, 1200
Pfizer Investigational Site
Montevideo, Uruguay
Sponsors and Collaborators
Pfizer
Investigators
Layout table for investigator information
Study Director: Pfizer CT.gov Call Center Pfizer

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer Inc
ClinicalTrials.gov Identifier: NCT00141193     History of Changes
Other Study ID Numbers: EQ4-00-02-018
A3191107
First Posted: September 1, 2005    Key Record Dates
Last Update Posted: August 6, 2008
Last Verified: August 2008

Additional relevant MeSH terms:
Layout table for MeSH terms
Adenoma
Adenomatous Polyps
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Celecoxib
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action